Clinical Trial Update: A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial of the recombinant Hepatitis E vaccine (expressed in Escherichia coli) has completed. The sponsor is Xiamen Innovax Biotech Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis E

Drugs mentioned

• Hecolin (HEV-239 recombinant vaccine)

Snippet

Sponsor: Xiamen Innovax Biotech Co., Ltd | Conditions: Hepatitis E | Phase 4 | Status: COMPLETED